CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 4, 1998, Pages 332-340

  Liu, Zhiyuan ^a,c   Cumberland, William G ^a   Hultin, Lance E ^b   Kaplan, Andrew H ^b   Detels, Roger ^a   Giorgi, Janis V ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Division of Communicable Diseases   (United States)

Author keywords

CD38 antigen; Flow cytometry; Immune activation; Prognostic marker; Quantitative fluorescence

Indexed keywords

ARTICLE; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032146161     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808010-00004     Document Type: Article

References (57)

1. Jassoy C, Walker B. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Semin Immunol 1997;18:341-54.
2. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-6.
3. + T cells. Science 1995;270:1811-15.
4. Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16. Nature 1995;378:563.
5. Rinaldo C, Huang X-L, Fan Z, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995; 69:5838-42.
6. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-56.
7. Deterre P, Gelman L, Gary-Gouy H, et al. Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1: possible role in the recycling of nicotinamide adenine dinucleotide metabolites. J Immunol 1996; 157:1381-8.
8. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today 1994;15:95-7.
9. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992;90:376-82.
10. + T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993;6:904-12.
11. + T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Commun Clin Cytometry 1996;26:1-7.
12. + cell count, soluble immune activation markers or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83-92.
13. + cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993;150:3070-9.
14. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
15. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
16. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
17. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
18. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996;271:1582-6.
19. + cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996;10:F17-22.
20. + T cell turnover. Science 1996;274:1543-7.
21. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-6.
22. Gorochov G, Kereveur A, Parizot C, et al. TCR-β repertoire complexity and evolution of HIV infection: influence of anti-retroviral regimens including protease inhibitors. Presented at the IV Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
23. Chmiel JS, Detels R, Kaslow RA, Van Raden M, Kingsley LA, Brookmeyer R, and the Multicenter AIDS Cohort Study Group. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol 1987;126:568-77.
24. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-18.
25. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(No. RR-17):1-19.
26. Bass HZ, Hardy WD, Mitsuyasu RT, Wang Y-X, Cumberland W, Fahey JL. Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment. J Acquir Immune Defic Syndr 1992;5:890-7.
27. Schenker EL, Hultin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry 1993;14:307-17.
28. Hultin L, Matud J, Giorgi JV. Tight regulation of CD4 antigen expression on lymphocytes of healthy donors used directly as a fluorescence quantitation standard. Cytometry 1996;(Suppl 8):90.
29. Cox DR. Regression models and life-tables. J R Stat Sac 1972;34: 187-220.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. SAS Institute. SAS/STAT user's guide, ed 4. Cary, NC: SAS Institute Inc., 1989:1027-69.
32. SAS Institute. SAS technical report P-229, SAS/STAT software: changes and enhancements, release 6.01. Cary, NC: SAS Institute. 1992:433-80.
33. Fuchs D, Jäger H, Popescu M, et al. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 1990;26:75-80.
34. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. BMJ 1988;296:745-50.
35. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
36. Godfried MH, van der Poll T, Weverling GJ, et al. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-45.
37. Stites DP, Moss AR, Bacchetti P, et al. Lymphocyte subset analysis to predict progression to AIDS in a cohort of homosexual men in San Francisco. Clin Immunol Immunopathol 1989;52:96-103.
38. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-24.
39. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
40. Mellors JW, Kingsley LA, Rinaldo CR Jr., et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
41. + lymphocyte activity. J Infect Dis 1995;172:329-39.
42. Bouscarat F, Levacher-Clergeot M, Dazza M-C, et al. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patient infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996; 12:17-24.
43. + subsets in acute EBV infection: comparison with chronic HIV disease. J Infect Dis 1998;177:1083-7.
44. Zarling JM, Ledbetter JA, Sias J, et al. HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. J Immunol 1990;144:2992-8.
45. + T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci USA 1990;87:4818-22.
46. Prince HE, Jensen ER. HIV-related alterations in CD8 cell subsets defined by in vitro survival characteristics. Cell Immunol 1991; 134:276-86.
47. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996;156:3509-20.
48. Pantaleo G, Fauci AS. New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995;13:487-512.
49. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996;2:405-11.
50. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94:1925-30.
51. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996;2:1-4.
52. + cell levels. J Infect Dis 1994;170:775-781.
53. Kelleher AD, Zaunders ACJ, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
54. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-16.
55. Lederman M, Connick E, Landay A, et al. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, ritonavir) preliminary results of ACTG 315. Presented at the IV Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
56. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
57. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997;126:939-45.